. "3 Programs for and Approaches to Treating Obesity." Weighing the Options: Criteria for Evaluating Weight-Management Programs. Washington, DC: The National Academies Press, 1995.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Weighing the Options: Criteria for Evaluating Weight-Management Programs
Anorex; Obalan; Phendiet; Plegine; Wehless; and others
5–12
35
70–210
Diethylpropion
IV
Tenuate; Tepanol
4–6
25; 75 (slow release)
75
Mazindol
IV
Mazanor; Sanorex
10
1 or 2
1–3
Phentermine
IV
Fastin; Ionamin; Phentrol; Adipex-P; and others
12–24
8; 15; 30
15–37.5
Phenylpropanolamine
Over the counter
Dexatrim
7–24
25 or 75
25–75
Serotonergic agents
Fenfluramine (d- or d-l)
IV
Pondimin
11–30
20
60–120
Fluoxetine
Not scheduled
Prozac; Lovan
24–72
20; 60
60
a DEA = Drug Enforcement Agency. See box titled ''Unreasonable Standards for Anti-Obesity Drugs?" for an explanation of the schedule classification.
SOURCE: Reproduced with permission, from G.A. Bray. Use and abuse of appetite-suppressant drugs in the treatment of obesity. Ann. Intern. Med. 1993;119:707–713.
